Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Twenty-five-ingredient Pearl Pill (Ershiwuwei Zhenzhu Wan) is a traditional Tibetan medicine (TTM) formulation first documented in the 8th-century classic text, the Four Medical Tantras. It is a multi-ingredient preparation composed of 25 distinct plant, animal, and mineral-derived substances, including pearl (margarita), pearl mother (margaritifera concha), nutmeg, saffron, and artificial musk. The formulation is widely used in China for the treatment of cerebrovascular and neurological disorders, particularly ischemic stroke, hemiplegia, facial paralysis, epilepsy, and vascular dementia. Preclinical studies suggest that it exerts neuroprotective, anti-inflammatory, and antioxidant effects, potentially by reducing the expression of inflammatory cytokines (such as TNF-alpha, IL-1beta, and IL-6), increasing superoxide dismutase (SOD) and catalase (CAT) activities, and inhibiting neuronal apoptosis through the upregulation of Bcl-2 and downregulation of caspase-3.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Twenty-five-ingredient Pearl Pill.
Work on Twenty-five-ingredient Pearl Pill? Claim this page to correct or add information. Claim this page